SCHEMBL5914145

SCHEMBL5914145

CNS(=O)(=O)c1nccc(N(C)c2nccc(-c3ccccc3)n2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IKBKB O14920 2/20 0.37
▸ AURKA O14965 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.36
▸ PRKACA P17612 1/20 0.36
▸ ADORA2A P29274 1/20 0.36
▸ BPTF Q12830 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ MAPK13 O15264 1/20 0.34
▸ RAF1 P04049 1/20 0.34
▸ MAPK9 P45984 1/20 0.34
▸ MAPK12 P53778 1/20 0.34
▸ MAPK11 Q15759 1/20 0.34
▸ MAPK14 Q16539 1/20 0.34
▸ HRH4 Q9H3N8 2/20 0.34
▸ LMNA P02545 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5316687 0.88 LMNA (0.38) IKBKBAURKAHSP90AA1PRKACAADORA2A
SCHEMBL5913956 0.73 NPSR1 (0.44) AURKAHSP90AA1PRKACAADORA2AMEN1
SCHEMBL5914308 0.71 AURKA (0.39) IKBKBAURKAHSP90AA1PRKACAADORA2A
SCHEMBL10973666 0.71 GSK3B (0.55) AURKAHSP90AA1PRKACAADORA2AMEN1
SCHEMBL4004337 0.71 KDR (0.34) IKBKBMEN1KMT2ALMNACYP3A4
SCHEMBL5914306 0.69 MKNK1 (0.47) HRH4CDK2VCP
SCHEMBL28886710 0.69 AURKA (0.55) AURKAHSP90AA1PRKACAADORA2AMEN1
SCHEMBL7257946 0.68 NR3C2 (0.45) IKBKBGSK3BDYRK1ACDK2DKK1
SCHEMBL14507076 0.68 IKBKB (0.46) IKBKBAURKAHSP90AA1PRKACAADORA2A
SCHEMBL4447801 0.68 BPTF (0.54) IKBKBAURKAHSP90AA1PRKACAADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060069110-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. 2006-03-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069110-A1 Substituted heterocyclic compounds and methods of use MAPT, MYLK2, IAPP IKBKB 892/4885AURKA 2082/4885HSP90AA1 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback